Close Menu

SAN FRANCISCO (GenomeWeb) – Guardant Health plans to launch a research-use only version of a liquid biopsy assay for cancer recurrence monitoring later this month, CEO Helmy Eltoukhy said at the Business in Personalized Medicine Summit in Millbrae, California last week.

During a presentation at the meeting, Eltoukhy provided an update on the firm's program to develop cell-free DNA assays for cancer recurrence monitoring and early detection.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
27
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.